US › Healthcare

Nautilus Biotechnology Inc (NAUT)

US · Healthcare · Biotechnology

$0.97-0.04%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$190,000

Net profit

$-14.5M

EPS

$-0.11

EPS estimate

$-0.14

Net margin

-7,615.3%

EPS came in at -0.11 against a street estimate of -0.14 — a beat of 21.4%.

Key statistics

Market cap

$113.2M

Forward P/E

0.0

P/B

0.88

Book value

$1.03

EPS (TTM)

$-0.44

52-week high

$4.31

52-week low

$0.68

50-day MA

$1.20

200-day MA

$2.13

Beta

0.87

Analyst view

Analysts rate Nautilus Biotechnology Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $4.00.

Shareholding

Insiders

32.02%

Institutions

44.15%

Largest institutional holders

Fund	Stake
Perceptive Advisors LLC	9.90%
Cercano Management LLC	5.64%
Vanguard Capital Management, LLC	2.00%
Hartland & Co	1.83%
Comprehensive Financial Management LLC	1.73%
Sentinel Trust CO Lba	0.59%
Acadian Asset Management LLC	0.58%
Geode Capital Management, LLC	0.47%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nautilus Biotechnology Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.